Physician Perspectives 2017: Use of ustekinumab in IBD
This Physician Perspectives survey focuses on the use of ustekinumab in IBD.
UST appears to be the preferred non-TNF biologic for treatment of moderate-to-severe Crohn’s disease, most frequently prescribed after the failure of one or two anti-TNFs (most often IFX & ADA), and before VDZ.
73% of physicians reported having had high expectations of UST's efficacy, and 58% stated that these expectations had been met, while 12% stated that they had not been met.
Majority of physicians expected UST to be somewhat effective or effective to treat UC patients with left-sided UC, non-acute, steroid dependent UC, extensive UC, ulcerative proctitis, acute severe colitis, and to treat patients with a high BMI.
The report includes following topics -
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook